Eric JD - Nurix Therapeutics Chief Officer
| NRIX Stock | USD 22.64 0.15 0.66% |
Executive
Eric JD is Chief Officer of Nurix Therapeutics
| Age | 57 |
| Address | 1700 Owens Street, San Francisco, CA, United States, 94158 |
| Phone | 415 660 5320 |
| Web | https://www.nurixtx.com |
Nurix Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2946) % which means that it has lost $0.2946 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5796) %, meaning that it created substantial loss on money invested by shareholders. Nurix Therapeutics' management efficiency ratios could be used to measure how well Nurix Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.49 in 2024. Return On Capital Employed is likely to drop to -0.55 in 2024. At this time, Nurix Therapeutics' Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 5.7 M in 2024, whereas Total Assets are likely to drop slightly above 318.1 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Huw Nash | Stoke Therapeutics | 57 | |
| Ronald Peck | Arvinas | N/A | |
| Mahesh Padval | Relay Therapeutics | N/A | |
| Christian MBA | Sana Biotechnology | 41 | |
| Roy Pollock | C4 Therapeutics | N/A | |
| Jeremy Chadwick | Kymera Therapeutics | 61 | |
| Alfonso MD | Foghorn Therapeutics | 53 | |
| Jasmin Tower | Generation Bio Co | N/A | |
| Madhu Pudipeddi | Prelude Therapeutics | N/A | |
| Greg Mann | Nkarta Inc | N/A | |
| JD Esq | Kymera Therapeutics | 65 | |
| Shamim MS | Stoke Therapeutics | 64 | |
| Mr MBA | C4 Therapeutics | 46 | |
| Jim Watters | Relay Therapeutics | N/A | |
| Steve Weiss | Arvinas | 54 | |
| Philip JD | Monte Rosa Therapeutics | 45 | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| Bryant JD | Prelude Therapeutics | 53 | |
| Edmund Dunn | Monte Rosa Therapeutics | 58 | |
| Lindsey Trickett | Prelude Therapeutics | N/A | |
| Magnus DPHIL | Monte Rosa Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.29 |
Nurix Therapeutics Leadership Team
Elected by the shareholders, the Nurix Therapeutics' board of directors comprises two types of representatives: Nurix Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nurix. The board's role is to monitor Nurix Therapeutics' management team and ensure that shareholders' interests are well served. Nurix Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nurix Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stefani Wolff, COO Devel | ||
| Arthur MD, Founder Board | ||
| Christine JD, Secretary Officer | ||
| John Kuriyan, Founder Board | ||
| JD Esq, VP Counsel | ||
| Cristiana Guiducci, Senior Research | ||
| Pasit Phiasivongsa, Chief Officer | ||
| Pr MD, Founder Board | ||
| Rita Kwong, Accounting Mang | ||
| Johannes Houte, Chief Officer | ||
| Christine Ring, G Sec | ||
| Gwenn Hansen, Chief Officer | ||
| Eric JD, Chief Officer | ||
| Michael Rap, Founder Board | ||
| Jason Kantor, Chief Officer |
Nurix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nurix Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (4.34) % | ||||
| Current Valuation | 1.16 B | ||||
| Shares Outstanding | 70.84 M | ||||
| Shares Owned By Insiders | 1.45 % | ||||
| Shares Owned By Institutions | 98.27 % | ||||
| Number Of Shares Shorted | 9.46 M | ||||
| Price To Book | 4.20 X | ||||
| Price To Sales | 28.08 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.